94 related articles for article (PubMed ID: 22679560)
1. KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer.
Caiola E; Rulli E; Fruscio R; Buda A; Broggini M; Marabese M
Am J Cancer Res; 2012; 2(3):298-308. PubMed ID: 22679560
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
Uvirova M; Simova J; Kubova B; Dvorackova N; Tomaskova H; Sedivcova M; Dite P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):466-71. PubMed ID: 26077004
[TBL] [Abstract][Full Text] [Related]
3. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.
Smits KM; Paranjape T; Nallur S; Wouters KA; Weijenberg MP; Schouten LJ; van den Brandt PA; Bosman FT; Weidhaas JB; van Engeland M
Clin Cancer Res; 2011 Dec; 17(24):7723-31. PubMed ID: 21994416
[TBL] [Abstract][Full Text] [Related]
4. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.
Sebio A; Paré L; Páez D; Salazar J; González A; Sala N; del Río E; Martín-Richard M; Tobeña M; Barnadas A; Baiget M
Pharmacogenet Genomics; 2013 Mar; 23(3):142-7. PubMed ID: 23324806
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Role of the KRAS Gene Polymorphism LCS6 (rs61764370) in Iraqi Women with Ovarian Cancer.
Ghazi Jumaa M
Arch Razi Inst; 2022 Feb; 77(1):205-211. PubMed ID: 35891756
[TBL] [Abstract][Full Text] [Related]
6. The relationship between
Çintesun FNİ; Kerimoğlu ÖS; Çintesun E; Nergiz S; Acar H; Çelik Ç
J Obstet Gynaecol; 2020 Oct; 40(7):988-993. PubMed ID: 31790621
[TBL] [Abstract][Full Text] [Related]
7. Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.
Kjersem JB; Ikdahl T; Guren T; Skovlund E; Sorbye H; Hamfjord J; Pfeiffer P; Glimelius B; Kersten C; Solvang H; Tveit KM; Kure EH
BMC Cancer; 2012 Nov; 12():534. PubMed ID: 23167843
[TBL] [Abstract][Full Text] [Related]
8. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.
Graziano F; Canestrari E; Loupakis F; Ruzzo A; Galluccio N; Santini D; Rocchi M; Vincenzi B; Salvatore L; Cremolini C; Spoto C; Catalano V; D'Emidio S; Giordani P; Tonini G; Falcone A; Magnani M
Pharmacogenomics J; 2010 Oct; 10(5):458-64. PubMed ID: 20177422
[TBL] [Abstract][Full Text] [Related]
9. The let-7 microRNA binding site variant in KRAS as a predictive biomarker for head and neck cancer patients with lymph node metastasis.
Ulusan M; Sen S; Yilmazer R; Dalay N; Demokan S
Pathol Res Pract; 2022 Nov; 239():154147. PubMed ID: 36228348
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.
Hollestelle A; Pelletier C; Hooning M; Crepin E; Schutte M; Look M; Collee JM; Nieuwlaat A; Dorssers LC; Seynaeve C; Aulchenko YS; Martens JW; van den Ouweland AM; Weidhaas JB
Breast Cancer Res Treat; 2011 Jul; 128(1):79-84. PubMed ID: 20676756
[TBL] [Abstract][Full Text] [Related]
11. No evidence for genetic association with the let-7 microRNA-binding site or other common KRAS variants in risk of endometriosis.
Luong HT; Nyholt DR; Painter JN; Chapman B; Kennedy S; Treloar SA; Zondervan KT; Montgomery GW
Hum Reprod; 2012 Dec; 27(12):3616-21. PubMed ID: 23010532
[TBL] [Abstract][Full Text] [Related]
12. KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer.
Nelson HH; Christensen BC; Plaza SL; Wiencke JK; Marsit CJ; Kelsey KT
Lung Cancer; 2010 Jul; 69(1):51-3. PubMed ID: 19854534
[TBL] [Abstract][Full Text] [Related]
13. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease.
Ruzzo A; Graziano F; Vincenzi B; Canestrari E; Perrone G; Galluccio N; Catalano V; Loupakis F; Rabitti C; Santini D; Tonini G; Fiorentini G; Rossi D; Falcone A; Magnani M
Oncologist; 2012; 17(6):823-9. PubMed ID: 22584434
[TBL] [Abstract][Full Text] [Related]
14. A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers.
Christensen BC; Moyer BJ; Avissar M; Ouellet LG; Plaza SL; McClean MD; Marsit CJ; Kelsey KT
Carcinogenesis; 2009 Jun; 30(6):1003-7. PubMed ID: 19380522
[TBL] [Abstract][Full Text] [Related]
15. Benefit of cetuximab addition to a platinum-fluorouracil-based chemotherapy according to KRAS-LCS6 variant in an unselected population of recurrent and/or metastatic head and neck cancers.
Bastit V; Bon-Mardion N; Picquenot JM; Rainville V; Moldovan C; François A; Loeb A; Thureau S; Manu D; Jardin F; Marie JP; Di Fiore F; Clatot F
Eur Arch Otorhinolaryngol; 2019 Feb; 276(2):541-550. PubMed ID: 30523411
[TBL] [Abstract][Full Text] [Related]
16. Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR).
Ganzinelli M; Rulli E; Caiola E; Garassino MC; Broggini M; Copreni E; Piva S; Longo F; Labianca R; Bareggi C; Fabbri MA; Martelli O; Fagnani D; Locatelli MC; Bertolini A; Valmadre G; Pavese I; Calcagno A; Sarobba MG; Marabese M
Sci Rep; 2015 Nov; 5():16331. PubMed ID: 26573509
[TBL] [Abstract][Full Text] [Related]
17. A let-7 microRNA polymorphism in the KRAS 3'-UTR is prognostic in oropharyngeal cancer.
De Ruyck K; Duprez F; Ferdinande L; Mbah C; Rios-Velazquez E; Hoebers F; Praet M; Deron P; Bonte K; Speel EJ; Libbrecht L; De Neve W; Lambin P; Thierens H
Cancer Epidemiol; 2014 Oct; 38(5):591-8. PubMed ID: 25127693
[TBL] [Abstract][Full Text] [Related]
18. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
Ratner E; Lu L; Boeke M; Barnett R; Nallur S; Chin LJ; Pelletier C; Blitzblau R; Tassi R; Paranjape T; Hui P; Godwin AK; Yu H; Risch H; Rutherford T; Schwartz P; Santin A; Matloff E; Zelterman D; Slack FJ; Weidhaas JB
Cancer Res; 2010 Aug; 70(16):6509-15. PubMed ID: 20647319
[TBL] [Abstract][Full Text] [Related]
19. Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels.
Crowley EH; Arena S; Lamba S; Di Nicolantonio F; Bardelli A
Hum Mutat; 2014 Feb; 35(2):208-14. PubMed ID: 24282149
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
Fernández-Mateos J; Seijas-Tamayo R; Mesía R; Taberna M; Pastor Borgoñón M; Pérez-Ruiz E; Adansa Klain JC; Vázquez Fernández S; Del Barco Morillo E; Lozano A; González Sarmiento R; Cruz-Hernández JJ;
Oral Oncol; 2016 Dec; 63():38-43. PubMed ID: 27938998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
